Drug news
UK court rules AstraZeneca's patent on Seroquel XR is invalid
The UK High Court has ruled that AstraZeneca's patent on the extended-release version of Seroquel XR (quetiapine fumarate) is invalid. The patent had been challenged by Accord Healthcare, Intas Pharmaceuticals, Novartis' Hexal and Sandoz generics units and Teva. The UK ruling is the first that says the patent is invalid, in contrast to the decision in March by the District Court in The Hague, Netherlands that supported its validity.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins